MedImmune LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease
Phase 2
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- Biological: Placebo IVBiological: MEDI6012Biological: Placebo SC
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2018-03-19
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 48
- Registration Number
- NCT02601560
- Locations
- 🇺🇸
Research Site, Falls Church, Virginia, United States
A Study in Adult Subjects With Select Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: MEDI1873
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 40
- Registration Number
- NCT02583165
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.
Phase 1
Completed
- Conditions
- HER2 Expressing Breast or Gastric/Stomach Cancers
- Interventions
- Biological: MEDI4276
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2019-06-18
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 47
- Registration Number
- NCT02576548
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 53
- Registration Number
- NCT02556463
- Locations
- 🇫🇷
Research Site, Villejuif, France
MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)
Phase 1
Completed
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 32
- Registration Number
- NCT02549651
- Locations
- 🇬🇧
Research Site, Leicester, United Kingdom
A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 113
- Registration Number
- NCT02548585
- Locations
- 🇩🇪
Research Site, Neuss, Germany
A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Biological: PlaceboBiological: MEDI-4166
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 103
- Registration Number
- NCT02524782
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis
Phase 2
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Biological: PlaceboBiological: MEDI9929
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 113
- Registration Number
- NCT02525094
- Locations
- 🇳🇿
Research Site, Wellington, New Zealand
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 433
- Registration Number
- NCT02519348
- Locations
- 🇨🇳
Research Site, Taoyuan City, Taiwan
A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: MEDI9929, 140 mg
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2017-06-21
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 21
- Registration Number
- NCT02512900
- Locations
- 🇵🇱
Research Site, Łódź, Poland
© Copyright 2025. All Rights Reserved by MedPath